These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 19441898)

  • 1. A review of multiple approaches towards an improved hepatitis B vaccine.
    Sanyal G; Shi L
    Expert Opin Ther Pat; 2009 Jan; 19(1):59-72. PubMed ID: 19441898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bicistronic woodchuck hepatitis virus core and gamma interferon DNA vaccine can protect from hepatitis but does not elicit sterilizing antiviral immunity.
    Wang J; Gujar SA; Cova L; Michalak TI
    J Virol; 2007 Jan; 81(2):903-16. PubMed ID: 17079319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination against hepatitis A and B: developments, deployment and delusions.
    Zuckerman JN
    Curr Opin Infect Dis; 2006 Oct; 19(5):456-9. PubMed ID: 16940869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New vaccination strategies for low- and non-responders to hepatitis B vaccine.
    Rendi-Wagner P; Wiedermann G; Stemberger H; Kollaritsch H
    Wien Klin Wochenschr; 2002 Mar; 114(5-6):175-80. PubMed ID: 12238305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA vaccines for prophylactic or therapeutic immunization against hepatitis B virus.
    Davis HL
    Mt Sinai J Med; 1999 Mar; 66(2):84-90. PubMed ID: 10100411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ability of Hepatitis B surface antigen DNA vaccine to elicit cell-mediated immune responses, but not antibody responses, was affected by the deglysosylation of S antigen.
    Xing Y; Huang Z; Lin Y; Li J; Chou TH; Lu S; Wang S
    Vaccine; 2008 Sep; 26(40):5145-52. PubMed ID: 18462847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B vaccine nonresponse and celiac disease.
    Noh KW; Poland GA; Murray JA
    Am J Gastroenterol; 2003 Oct; 98(10):2289-92. PubMed ID: 14572581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience with hepatitis A and B vaccines.
    Davis JP
    Am J Med; 2005 Oct; 118 Suppl 10A():7S-15S. PubMed ID: 16271535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvanted hepatitis B vaccine: new drug. Patients with renal failure: similar response rate but fewer boosters needed.
    Prescrire Int; 2008 Dec; 17(98):234-6. PubMed ID: 19422145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pattern of T cell activation in absence of protective immunity against hepatitis B virus. Review].
    Goncalves L; Barboza L; Albarrán B; Salmen S; Montes H; Hernández M; Berrueta L
    Invest Clin; 2006 Mar; 47(1):83-96. PubMed ID: 16562647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel approaches to new therapies for hepatitis B virus infection.
    Loomba R; Liang TJ
    Antivir Ther; 2006; 11(1):1-15. PubMed ID: 16518955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant hepatitis B triple antigen vaccine: Hepacare.
    Zuckerman JN; Zuckerman AJ
    Expert Rev Vaccines; 2002 Aug; 1(2):141-4. PubMed ID: 12901552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress in the prevention and control of viral hepatitis type B: closing remarks.
    Rizzetto M; Zanetti AR
    J Med Virol; 2002 Jul; 67(3):463-6. PubMed ID: 12116047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the effects of biodegradable nanoparticles on a vaccine delivery system using AFM, SEM, and TEM.
    Kim BG; Kang IJ
    Ultramicroscopy; 2008 Sep; 108(10):1168-73. PubMed ID: 18554804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved immunization practices reduce childhood hepatitis B infection in Tonga.
    Danielsson N; Fakakovikaetau T; Szegedi E
    Vaccine; 2009 Jul; 27(33):4462-7. PubMed ID: 19508908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New hepatitis B vaccine formulated with an improved adjuvant system.
    Kundi M
    Expert Rev Vaccines; 2007 Apr; 6(2):133-40. PubMed ID: 17408363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-glycoglycosphingolipid-induced augmentation of the anti-HBV immune response is associated with altered CD8 and NKT lymphocyte distribution: a novel adjuvant for HBV vaccination.
    Mizrahi M; Lalazar G; Ben Ya'acov A; Livovsky DM; Horowitz Y; Zolotarov L; Adler R; Shouval D; Ilan Y
    Vaccine; 2008 May; 26(21):2589-95. PubMed ID: 18423947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the adjuvanticity of aluminum salts and their combination in hepatitis B recombinant protein vaccine in assessed mice.
    Mahboubi A; Fazeli MR; Dinarvand R; Samadi N; Sharifzadeh M; Ilka H; Azadi S; Soleimanian R; Kalkouei H; Hajikhanmirzaei R; Valadkhani M
    Iran J Immunol; 2008 Sep; 5(3):163-70. PubMed ID: 18791283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccines and immunotherapies against hepatitis B and hepatitis C viruses.
    Inchauspé G; Michel ML
    J Viral Hepat; 2007 Nov; 14 Suppl 1():97-103. PubMed ID: 17958650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis on economic efficacy regarding previous strategies and current recommendations for vaccination against hepatitis B virus in China].
    Zhang SX; Dang RB; Zhang WD; Liang XF; Cui FQ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Oct; 29(10):1003-8. PubMed ID: 19173882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.